is aspirin the answer for everyone?

A new study has sparked a fresh debate about whether every pregnant woman should be prescribed low‑dose aspirin.

Current practice and the appeal of a universal approach

For years, low‑dose aspirin has been recommended for women identified as high‑risk for pre‑eclampsia, a condition that can cause high blood pressure and organ damage. The argument for extending aspirin to all pregnant women is simple: existing screening tools are imperfect, and pre‑eclampsia can be difficult to predict.

Aspirin is inexpensive, widely available, and generally safe, which makes a blanket recommendation tempting. However, medicine rarely succeeds with a one‑size‑fits‑all strategy, especially when we lack reliable early‑pregnancy markers for placental insufficiency.

Did You Know? Low‑dose aspirin works by reducing the stickiness of platelets, helping maintain healthy blood flow between mother and baby.

How aspirin may help

In pre‑eclampsia, the placenta can trigger inflammation and over‑active platelets, compromising blood flow to the fetus. By making platelets less likely to clump, aspirin can improve circulation and potentially lessen the severity of the condition.

In other fields, such as cardiology, routine low‑dose aspirin for healthy older adults was recently reconsidered after studies showed that long‑term bleeding risks outweighed benefits. Pregnancy offers a much shorter treatment window—typically only a few months—so the risk of serious bleeding in otherwise healthy young women is low, while the stakes of pre‑eclampsia are high.

Limitations of a universal dose

Standard low‑dose regimens may be insufficient for women with higher body‑mass index or greater blood volume. Absorption can also vary, especially with enteric‑coated tablets or the digestive changes that accompany pregnancy. Inconsistent use further reduces effectiveness.

At present, clinicians base aspirin eligibility largely on a woman’s medical history and known risk factors. This straightforward method can miss some cases of pre‑eclampsia while treating others who may never develop the condition.

Advanced testing: promise and practicality

Combining medical history with blood‑pressure monitoring, placental blood‑test markers, and targeted ultrasound can identify more women at risk. The drawback is that such testing requires specialist training, additional equipment, and extra time—resources that are not always available in routine care.

Expert Insight: Samantha Carter notes that while aspirin’s safety profile makes it attractive, the variability in dose response and absorption underscores the need for better risk stratification. Without reliable early biomarkers, a blanket policy may lead to overtreatment for some and missed opportunities for others.

The future: better biomarkers

Research into platelet‑derived extracellular vesicles—a type of microscopic signal released by cells—could reveal how the placenta and maternal environment interact months before symptoms appear. If such biomarkers become clinically viable, they may guide personalized aspirin therapy, ensuring that only those who truly need it receive it.

Until such tools are widely accessible, women prescribed aspirin during pregnancy should continue the regimen, as it remains a safe, evidence‑based option for those at higher risk of pre‑eclampsia.

Frequently Asked Questions

What is pre‑eclampsia?

Pre‑eclampsia is a dangerous pregnancy complication that can cause high blood pressure and organ damage.

How does low‑dose aspirin help prevent pre‑eclampsia?

Aspirin reduces platelet stickiness, which can improve blood flow between mother and baby and counteract the inflammation and platelet over‑activity associated with pre‑eclampsia.

Who currently receives low‑dose aspirin during pregnancy?

Doctors typically prescribe low‑dose aspirin to women identified as high‑risk for pre‑eclampsia based on their medical history and known risk factors.

What are your thoughts on the possibility of using low‑dose aspirin as a routine part of prenatal care?